U.S. markets close in 6 hours 23 minutes

Bio-Path Holdings, Inc. (BPTH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.79-0.06 (-0.88%)
As of 9:36AM EDT. Market open.
Sign in to post a message.
  • G
    Grateful
    Did anyone see news released?
  • m
    mark
    Given the valuations afforded to the comps, three product candidates under development addressing sizable target markets with unmet
    medical needs and supported by a novel and proprietary technology platform, and the impressive results recently announced, it appears that
    BPTH remains clearly undervalued at current levels.
  • A
    Al
    BIG NEWS COMING
    Bullish
  • m
    mark
    buy today ,or will cry tomorrow
  • B
    Brian
    I'm sitting on 69 shares at an average of $6.50. Can't wait for it to perk up once prexigebersen is all over cancer wards.
    Bullish
  • F
    Franklin
    This needs to just have a capitulation type day with a reversal an get it over with. Please
  • c
    callanta
    If you are interested in seeing some really solid transformation to your trading bottom line then you need to check out (http://Rightpicker.com).
  • S
    SONY
    6 soon
  • P
    Piercamania
    did they just halt this?
    Bullish
  • S
    SONY
    Buy ETH
  • J
    John
    9 soon
    Bullish
  • I
    Investor1
    See Everyone - this is not a real company. Peter and Doug are using shareholders to fund their research because they didn't have anything that the government would fund. They should both be in jail for fraud!
  • b
    bigbear
    This is a speculative stock (BPTH), and my plan is to let this stock bottom-out, and then double down on it. With the patents they own, a hungry Bio-tech company will come along and buy them out.
    The ’379 patent will offer target-specific protection for on-going clinical trials using prexigebersen in combination with decitabine as a treatment for acute myeloid leukemia (AML).
    For those of you that don’t what AML is it is one of the most deadly forms of Leukemia. I know way more about this then I ever wanted to know. A close family member came down with AML. About a one in ten chance of survival, the Great Doctors and God saved his life. He went thru a h—l you cannot imagine. He received a Stem cell Bone marrow transplant and he is now “Cured”. AML needs every new drug that is affective against it developed now.
    The chemo he was on, was very hard on the body, he had 69 bags of controlled poison. He is the strongest person I have ever known. We pray this company is super successful with this drug. By the way this young man is my son! Cured for 6 years now!
    Bullish
  • k
    kevin
    Pump and dump ; gave the insiders the opportunity to sell
  • M
    Moon
    Something is not right.... shares outstanding equivalent 1.76M and now 52M shares trading already.
  • R
    Rekaut
    I need some advice please. I bought 2000 shares for $ 2,08 and I have a feeling that may be a wrong decision. Should I sell them right know and take a lost, or is there any chance that it recover? Thanksss.
  • s
    silverman
    All investors, big and small will just let it free fall?
    Will not happen
  • J
    John
    Was checking this out and it appears that they sold a couple million of stock to their friends for around .65 cents a share back in October. I'm not a professional but that sure seems like the company doesn't value their stock much so I'm not sure why i should either.
  • P
    Pankaj
    Hope this company mgmt shares some good news today . We are due for huge run up .....Hope we can go above $20 soon
  • K
    Kev
    H.C. Wainwright analyst Yi Chen started Bio-Path Holdings with a Buy rating and $28 price target. The company possesses an "intriguing" technology platform, DNAbilize, consisting of a novel and proprietary way to achieve sustainable systemic delivery of antisense oligonucleotides, Chen tells investors in a research note. Further, the analyst believes prexigebersen could have broad applicability within hematological malignancies as well as solid tumors.